Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available

American Journal of Epidemiology

Volumn 183, Issue 8, 2016, Pages 758-764

  Hernán, Miguel A ^a,b   Robins, James M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

big data; causal inference; comparative effectiveness research; target trial

Indexed keywords

COMPARATIVE STUDY; DATA SET; EPIDEMIOLOGY; METHODOLOGY; RESEARCH WORK; SAFETY;

COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; DATA BASE; HUMAN; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL; THEORETICAL MODEL; ADVERSE EFFECTS; BREAST NEOPLASMS; CAUSALITY; COMBINATION DRUG THERAPY; ESTROGEN THERAPY; FACTUAL DATABASE; FEMALE; POSTMENOPAUSE; PROCEDURES; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS; STATISTICS AND NUMERICAL DATA;

GESTAGEN;

BREAST NEOPLASMS; CAUSALITY; COMPARATIVE EFFECTIVENESS RESEARCH; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; POSTMENOPAUSE; PROGESTINS; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84964378350     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwv254     Document Type: Article

References (57)

1. Greenwood V. Can big data tell us what clinical trials don't? The New York Times. October 3, 2014. http://www.nytimes. com/2014/10/05/magazine/can-big-data-tell-us-what-clinicaltrials-dont.html. Accessed September 4, 2015.
2. Hernán MA. With great data comes great responsibility: publishing comparative effectiveness research in epidemiology. Epidemiology. 2011;22(3):290-291.
3. Rubin DB. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol. 1974;66(5):688-701.
4. Robins JM. A new approach to causal inference in mortality studies with a sustained exposure period - application to control of the healthy worker survivor effect [published erratum appears in Math Model. 1987;14:917-921]. Math Model. 1986; 7(9-12):1393-1512.
5. Robins JM. Addendum to "a new approach to causal inference in mortality studies with a sustained exposure period - application to control of the healthy worker survivor effect" [published erratum appears in Comput Math Appl. 1989:18;477]. Comput Math Appl. 1987;14(9-12):923-945.
6. Robins JM, Hernán MA. Estimation of the causal effects of time-varying exposures. In: Fitzmaurice G, et al, eds. Longitudinal Data Analysis. New York, NY: Chapman and Hall/CRC Press; 2008:553-599.
7. Richardson WS,Wilson MC, Nishikawa J, et al. The well-built clinical question: a key to evidence-based decisions. ACP J Club. 1995;123(3):A12-A13.
8. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5): 615-625.
9. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmaticexplanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62(5):464-475.
10. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20(8):637-648.
11. Ray WA. Evaluating medication effects outside of clinical trials: New-user designs. Am J Epidemiol. 2003;158(9): 915-920.
12. Hernán MA, Robins JM. Observational studies analyzed like randomized experiments: best of both worlds. Epidemiology. 2008;19(6):789-792.
13. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766-779.
14. Hernán MA, Robins JM. Causal Inference. Boca Raton, FL: Chapman & Hall/CRC; 2016.
15. Glynn RJ, Knight EL, Levin R, et al. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology. 2001;12(6):682-689.
16. Schneeweiss S, Patrick AR, Stürmer T, et al. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007;45(10 suppl 2):S131-S142.
17. Robins JM. The analysis of randomized and non-randomized AIDS treatment trials using a new approach to causal inference in longitudinal studies. In: Sechrest L, Freeman H, Mulley A, eds. Health Services Research Methodology: A Focus on AIDS. Washington, DC: US Public Health Service National Center for Health Services Research; 1989:113-159.
18. Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21(3):383-388.
19. Gruber S, Logan RW, Jarrín I, et al. Ensemble learning of inverse probability weights for marginal structural modeling in large observational datasets. Stat Med. 2015;34(1):106-117.
20. Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20(4): 512-522.
21. Polley E, Rose S, Van der Laan M. Super learning. In: Van der Laan MJ, Rose S, eds. Targeted Learning. New York, NY: Springer; 2012:43-66.
22. Saunders KW, Dunn KM, Merrill JO, et al. Relationship of opioid use and dosage levels to fractures in older chronic pain patients. J Genl Intern Med. 2010;25(4):310-315.
23. García Rodríguez LA, Ruigómez A. Case validation in research using large databases. Br J Gen Pract. 2010;60(572): 160-161.
24. Ives DG, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study. Ann Epidemiol. 1995;5(4):278-285.
25. Hernán MA, Jick SS, Olek MJ, et al. Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology. 2004;63(5):838-842.
26. Hernán MA, Robins JM. Observational studies analyzed like randomized trials, and vice versa. In: Gatsonis C, Morton S, eds. Methods in Comparative Effectiveness Research. Boca Raton, FL: Chapman & Hall/CRC. In press.
27. Hernán MA, Hernández-Díaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9(1): 48-55.
28. Zhang Y, Thamer M, Kaufman J, et al. Comparative effectiveness of two anemia management strategies for complex elderly dialysis patients. Med Care. 2014;52(zuppl 3): S132-S139.
29. HIV-CAUSAL Collaboration, Cain LE, Logan R, et al. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med. 2011;154(8):509-515.
30. Danaei G, Pan A, Hu FB, et al. Hypothetical midlife interventions in women and risk of type 2 diabetes. Epidemiology. 2013;24(1):122-128.
31. van der Laan MJ, Petersen ML, Joffe MM. History-adjusted marginal structural models and statically-optimal dynamic treatment regimens. Int J Biostat. 2005;1(1):Article 4.
32. Petersen ML, Deeks SG, Martin JN, et al. History-adjusted marginal structural models for estimating time-varying effect modification. Am J Epidemiol. 2007;166(9):985-993.
33. Robins JM, Hernán MA, Rotnitzky A. Effect modification by time-varying covariates. Am J Epidemiol. 2007;166(9): 994-1002; discussion 1003-1004.
34. Danaei G, Rodríguez LA, Cantero OF, et al. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res. 2013;22(1):70-96.
35. Cain LE, Robins JM, Lanoy E, et al. When to start treatment? A systematic approach to the comparison of dynamic regimes using observational data. Int J Biostat. 2010;6(2):Article 18.
36. Orellana L, Rotnitzky A, Robins JM. Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, Part II: proofs of results. Int J Biostat. 2010; 6(2):Article 9.
37. Orellana L, Rotnitzky A, Robins JM. Dynamic regime marginal structural mean models for estimation of optimal dynamic treatment regimes, Part I: main content. Int J Biostat. 2010;6(2): Article 8.
38. van der Laan MJ, Petersen ML. Causal effect models for realistic individualized treatment and intention to treat rules. Int J Biostat. 2007;3(1):Article 3.
39. Robins JM, Rotnitzky A. Recovery of information and adjustment for dependent censoring using surrogate markers. In: Jewell N, Dietz K, Farewell V, eds. AIDS Epidemiology - Methodological Issues. Boston, MA: Birkhäuser; 1992:297-331.
40. Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7(3):e1000251.
41. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492-499.
42. Institute of Medicine. Ethical and Scientific Issues in Studying the Safety of Approved Drugs 2012. Washington, DC: The National Academies Press; 2012.
43. Sterne JAC, Higgins JPT, Reeves BC. The ROBINS-I tool (Risk Of Bias In Non-randomized Studies-of Interventions). Version 7. https://www.riskofbias.info. Accessed March 10, 2016.
44. Hernán MA, VanderWeele TJ. Compound treatments and transportability of causal inference. Epidemiology. 2011;22(3): 368-377.
45. Bareinboim E, Pearl J. External validity: from do-calculus to transportability across populations. Stat Sci. 2014;29(4): 579-595.
46. Robins JM, Orellana L, Rotnitzky A. Estimation and extrapolation of optimal treatment and testing strategies. Stat Med. 2008;27(23):4678-4721.
47. Madigan D, Stang PE, Berlin JA, et al. A systematic statistical approach to evaluating evidence from observational studies. Annu Rev Stat Appl. 2014;1:11-39.
48. Garcia-Albeniz X, Chan JM, Paciorek A, et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015;51(7):817-824.
49. Rose S, van der Laan MJ. A targeted maximum likelihood estimator for two-stage designs. Int J Biostatistics. 2011;7(1): Article 17.
50. King G, Zeng L, Chow S-C. Inference in Case Control Studies, in Encyclopedia of Biopharmaceutical Statistics. 3rd ed. New York, NY: Marcel Dekker; 2010.
51. Robins JM. Comment on "choice as an alternative to control in observational studies" by Paul Rosenbaum. Stat Sci. 1998; 14(3):281-293.
52. Tchetgen Tchetgen EJ, VanderWeele TJ. On causal inference in the presence of interference. Stat Methods Med Res. 2012; 21(1):55-75.
53. Hudgens MG, Halloran ME. Toward causal inference with interference. J Am Stat Assoc. 2008;103(482):832-842.
54. Sobel ME. What do randomized studies of housing mobility demonstrate? Causal inference in the face of interference. J Am Stat Assoc. 2006;101(476):1398-1407.
55. Petersen ML, Porter KE, Gruber S, et al. Diagnosing and responding to violations in the positivity assumption. Stat Methods Med Res. 2012;21(1):31-54.
56. Curtis LH, Weiner MG, Boudreau DM, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012; 21(suppl 1):23-31.
57. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012; 367(14):1355-1360.